Business
Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and
About this update from Cabaletta Bio, Inc.
[{"type":"text","content":"PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointments of Samik Basu, M.D. to Chief Scientific Officer (CSO) and Heather Harte-Hall to Chief Compliance Officer (CCO). In these new roles, Dr. Basu and Ms. Harte-Hall will continue to report to Gwendolyn Binder, Ph.D., Cabaletta Bio’s Executive Vice President of Science & Technology. “Samik and Heather are both highly respected and accomplished leaders at Cabaletta and we are thrilled to announce their well-deserved promotions to these new roles. Samik has demonstrated superior leadership guiding the preclinical research and translational medicine teams through the discovery and development of our deep pipeline of precision therapies for patients with B cell-mediated autoimmune diseases. Heather has established quality and compliance programs, which along with her insights and strategic guidance, have proven invaluable as we have advanced our pipeline, most notably our lead product candidate DSG3-CAART, in mucosal pemphigus vulgaris,” said Dr. Binder. “The addition of Samik and Heather to our leadership team positions us well to deliver on the next phase of our growth including the expansion of our laboratories, continued quality and compliance around our expanding manufacturing efforts and multiple clinical and corporate milestones related to our portfolio of potentially curative products for patients with B cell mediated autoimmune diseases,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. Dr. Basu joined Cabaletta in December 2019 and was most recently Vice President of Preclinical Research and Translational Medicine before assuming his new role as Chief Scientific Officer. Prior to joining Cabaletta, Dr. Basu was Head of Translational Sciences (Medicine) at Adaptimmune Therapeutics, plc, where he led research efforts focused on understanding the mechanisms of resistance and response to T-cell receptor based adoptive immunotherapies to inform next generation approaches and clinical strategies. Before that, Dr. Basu co-led preclinical development efforts for Keytruda® (pembrolizumab) at Merck Research Laboratories. He is...